<center id="49wez"><em id="49wez"></em></center>
      <code id="49wez"><small id="49wez"><optgroup id="49wez"></optgroup></small></code>
      <code id="49wez"><small id="49wez"><track id="49wez"></track></small></code>
      <th id="49wez"><option id="49wez"><acronym id="49wez"></acronym></option></th>

    1. <object id="49wez"></object>
      English | 中文版 | 手機版 企業登錄 | 個人登錄 | 郵件訂閱
      當前位置 > 首頁 > 行業資訊 > 展會 > 第五屆ADC藥物開發峰會通知

      第五屆ADC藥物開發峰會通知

      瀏覽次數:1096 發布日期:2023-12-5  來源:本站 本站原創,轉載請注明出處

      會議基本信息:
      會議名稱: 第五屆ADC藥物開發峰會
      會議地點: 蘇州,中國
      會議時間: 2024年3月1-2日

      會議背景
      截止到2023年10月,全世界范圍內共有15款ADC藥物獲批上市。尤其是從2018年至今,在科研單位及行業的努力下,ADC藥物的臨床療效取得了重大進展,以Enhertu為代表的ADC逐漸顯示出成為10億美元重磅炸彈的藥品趨勢,年復合增長率已經達到了40.4%。創新的偶聯技術平臺,優化的DARs值,改進的linker可以進一步的控制ADC的精準性、臨床療效、以及減少毒素副作用。在此背景下,中國的ADC藥物開發也成功的吸引了全世界的目標,投資,授權合作不斷。為此,我們將于2024年3月1-2日在蘇州,召開第五屆ADC藥物開發峰會。期待大家的出席!

      會議主題:
      M(主論壇). 全球ADC市場動態:投資與合作趨勢
      ADC藥物開發走進舞臺中央
      中國ADC藥物合作開發,國際大藥廠押注下一個重磅炸彈賽道
      ADC兼并,收購,合作的背后驅動力
      A1. 靶點發現、轉化醫學及臨床前開發
      創新靶點及生物標志物驗證
      ADC非臨床研究要點:藥理學、毒理學、安全性評價要點
      監管視角:ADC非臨床開發挑戰
      可驗證的端到端的ADC藥物發現平臺
      避免熱點靶點內卷、ADC開發的熱門方向
      A2: 臨床開發:全球化及腫瘤以外適應癥探索
      全球化多中心臨床的開發挑戰
      差異化臨床開發: 臨床策略提升ADC成功率
      ADC聯合治療方向:與化療Combo,
      超越腫瘤及血液瘤:ADC實體瘤進展與非腫瘤適應癥開發
      簡化臨床開發,加速推動候選分子從實驗室邁向臨床
      A3: 下一代創新偶聯治療實體
      新型作用機制下的新型有效負載:超越傳統毒素
      不斷創新的新型偶聯治療實體
      推動XDC進入臨床:創新設計以及控制開發風險
      創新偶聯治療實體分享:蛋白降解偶聯 / 多肽偶聯 / 雙抗偶聯 / 雙環肽的放射性偶聯 等等
      B1: 攜手共進:MNC & 本土Biotech合作
      ADC藥物更廣泛的治療窗口挑戰
      MNC與中國本土創新Biotech管線合作開發,開發進展協同挑戰
      全球ADC藥物開發背景下的中國機會
      下一步合作趨勢:擴大適應癥以及推進到一二線治療
      出海授權合作中的風險控制、知識產權保護
      資本視角:ADC藥物投資方向
      B2: 案例展示:創新ADC技術平臺
      全面革新ADC 設計:優化的抗體、可裂解的連接子、創新的毒素
      設計鏈接器以增加ADC 功效和降低毒性
      使用兩種不同的雙有效負載 ADC
      細胞毒素可降低藥物耐藥性
      新型ADC平臺:負載多樣化
      B3: 授權出海及商業化策略
      從PD-1授權出海中學到的經驗與啟示
      建立更廣泛的合作來擴展管線以及開拓海外市場
      與海外監管單位保持密切溝通,攜手合作方共同應對注冊申報挑戰
      急劇增長的ADC銷售份額共同應對海外市場商業化開發挑戰
      C1: 連接子 & 毒素 以及ADC的耐受性
      通過接頭設計: 提高功效、穩定性并減少脫靶毒性
      非內化的ADC開發
      ADC 毒性的影響和優化策略
      最小化毒性并提高耐受性, 以最大化 ADC 的治療效果
      免疫原性、旁觀者效應或系統性毒素以及快速清除
      C2: 選擇可靠的合作伙伴共同應對工藝挑戰
      確保ADC的產品質量、效力
      穩健可放大的工藝、支持快速工藝轉移
      如何協同小分子與大分子共同工藝優化的挑戰
      抗體工程化、藥物遞送策略
      應對不同偶聯ADC的下游高效純化
      全球ADC外包市場、如何選擇可靠的CDMO合作伙伴
      C3; 質量控制及生物分析策略
      識別和研究新型偶聯位點的快速表征分析
      推動CQA屬性落地,迎接生產挑戰
      解決ADC藥物特殊的生物分析挑戰
      復雜的結構對生物分析的影響
      與時俱進的生物分析工具
      ADC藥物的質量控制和藥代PK分析策略

      中文官網:https://www.bagevent.com/event/adc2024
       
      合作聯系:
      演講聯系人:Ada   18601610075   adaliu@chujietech.com
      贊助聯系人:Wilson  18662147488  wilsonwang@chujietech.com
       
       
      EN Version

      Event info:
      Name:The 5th ADC Development Summit (China Focus)
      Location: Suzhou,China
      Time: March 1-2,2024

      Event Background:
      As of October 30,2023, 15 ADC drugs had received approval worldwide.  Promising clinical benefits and significant advancements had been made by the effort from academic and industry since 2018.  For instance, Enhertu a groundbreaking treatment for HER2+ Cancer showing great potential to become blockbuster. The global ADC market in 2022 has grown to US$7.9 billion with a CAGR of 40.4% between 2018 and 2022. Innovation Conjugate platform, optimization of DASs and improved linker together improving ADC precision、clinical efficiency、reduced off-target toxicity。 China's ADC drug development has also successfully attracted investments, cooperation, and licensing out for big pharmaceuticals worldwide.  As for this background, we are going to launch the 5th ADC Development Summit in March 1-2, 2024. Suzhou, China.  We are looking forward to meeting you onsite!
        
      Event Topics
      Main Forum - Global ADC Investment and Cooperation
      ADCs Taking Center Stage
      Chinese Collaborations, Approvals and Expansions
      The Drivers Behind the Demand for ADCs
      A1: Target Selection and Preclinical Research
      Novel Biomarkers in ADC
      ADC Nonclinical Pharmacology, Toxicology Research and Safety Considerations
      Regulatory Perspective of ADC,Nonclinical Safety Assessments
      Validated, End-to-End ADC Discovery Platform
      Evolving Strategies for Target Selection for ADC
      A2: Clinical Development and Beyond Oncology
      Global Clinical Trials Challenge
      The Strategic Significance and Practice of Clinical Differentiation Development of ADC
      ADC Combination Therapy: Combining with Chemotherapy
      Exploring ADCs in Solid Tumor and Beyond Streamline the Clinical Path
      A3: Next-Generation Conjugates Modalities
      Emerging Different Types of Payloads with Novel Mechanism
      Increasing Investment for XDC
      Better Design and Bring XDC into Clinical
      Emerging New Modality :Degrader-Antibody Conjugates / Peptide Drug Conjugates / Dual-Site or Dual-Target ADCs / Bicycle Radio-Conjugates etc…
      B1: Collaboration Between MNC & China Biotech
      Wider Therapeutic Window Challenge
      Development Progress and Collaborative Challenges Between MNC and Chinese Biotech
      Global ADC Drug Development & China Opportunities
      Next Cooperation Trend: Expansion of Applications and Treatment lines
      Risk Management and Patent Protection
      B2: Novel ADC Platform Showcase
      Revolutionizing ADC Design: Optimized Antibodies, Cleavable Linkers, Innovative Payloads
      Designing Linkers to Increase ADC Efficacy and Reduce Toxicity
      Dual-Payload ADCs Using Two Different Cytotoxins to Reduce Resistance
      Novel ADC Platform: Payload Diversification
      B3: License-out & Commercialization Strategy
      Lessons Learned from PD-1 License-Out
      Broad Collaborations to Expand Pipelines and Explore Overseas Opportunities
      Together With Partner and Communicate with Regulatory Closely for IND Application
      Jointly Respond to the Commercial Development of Overseas Markets
      C1: Linker & Toxicities and ADC Tolerability
      Improve Efficacy, Stability, and Reduce Off-Target Toxicities with Linker Design
      Effects of ADC Toxicity and Optimization Strategies
      Minimizing Toxicities & Improving Tolerability to Maximize the Tl of ADCs
      Immunogenicity, Bystander or Systemic Toxicity, and Rapid Clearance
      C2: Process Development with Reliable Partner
      Ensuring Your ADC's Product Quality, Identity & Potency
      Optimizing ADC Process Development to Deliver on Accelerated Timelines
      Engineering, Delivery & Dosing Strategies
      Diversification of ADC Formats and Overcoming Purification Challenges
      C3: Quality Control and Bioanalytical Strategies
      Bioanalytical Strategies for ADC PK Analysis
      Rapid Characterization Methods to Identify and Investigate New Bioconjugation Sites
      Manufacturing Challenges and Trends
      Solving Unique ADC Bioanalytical Challenges State-of-the-art Bioanalytical Tools

      Event Website: https://www.bagevent.com/event/ADC2024EN

      Contact Us
      Speak Opportunity:Ada   18601610075   adaliu@chujietech.com
      Sponsor Opportunity:Wilson  18662147488  wilsonwang@chujietech.com


      用戶名: 密碼: 匿名 快速注冊 忘記密碼
      評論只代表網友觀點,不代表本站觀點。 請輸入驗證碼: 8795
      Copyright(C) 1998-2024 生物器材網 電話:021-64166852;13621656896 E-mail:info@bio-equip.com
      精品久久8x国产免费观看